Jan 16 2019

Barbara Binzak Blumenfeld, shareholder in the firm's FDA & Biotechnology practice, will present at the 6th Edition International IP 2019 Conclave & Awards in Mumbai, India. The session, “The 505(b)(2) Platform and the Next Generation of Pharma in the U.S.,” will cover the difficulties that generic drug sponsors experience in the U.S. and how a different kind of new drug application—a “505(b)(2)”—offers sponsors greater competitive advantages.